Research and experimental development on natural sciences and engineering
FIKKAN PHARMA AS
Revenue 2025
NOK 666,000
Operating profit
NOK 509,000
Equity
NOK 2.5m
Incorporated
2015
Share capital
NOK 30,000
Key figures · 2024
Current ratio
6.75
Equity ratio
91.5%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 76.3% | |
| Net margin (%%) | 143.9% | |
| Return on assets (%%) | 18.4% | |
| Likviditet | ||
| Current ratio | 6.75 | |
| Working capital | 1.3m | |
| Soliditet | ||
| Equity ratio (%%) | 91.5% | |
| Debt-to-equity ratio | 0.09 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.